Lung Cancer
Conditions
Brief summary
To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.
Interventions
BIOLOGICALherpes zoster vaccine
Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1.Male or female patients \>=18 years of age; 2.Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments; 3. Never received herpes zoster vaccine
Exclusion criteria
* Patients having other factors that preventing researchers from enrollment them.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of herpes zoster at 12 months | 12 months | During the 12-month follow-up period, the incidence of herpes zoster in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests. |
| Incidence of herpes zoster | 24 months | The proportion of lung cancer patients who developed herpes zoster during the study period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survival rate | 5 years | The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Immune response | 5 years | The immune response (such as antibody levels) of patients after vaccination is evaluated through serological testing. |
| Lung cancer-related complications | 5 years | Severity of herpes zoster and incidence of complications (e.g., postherpetic neuralgia) |
| Adverse reactions after vaccination | 30 days | Observe whether patients who receive the herpes zoster vaccine experience adverse reactions after vaccination, such as fever, redness, swelling and pain at the injection site, headache, dizziness, etc. |
| Length of hospital stay | 5 years | Record the number of days of hospitalization for patients hospitalized due to herpes zoster |
| Hospitalization rate | 5 years | The proportion of patients hospitalized due to herpes zoster or other related complications. |
Outcome results
None listed